Companion Diagnostics: Improving Drug Development and Medical Practice

Companion diagnostics (CDx), which identifies and detects biomarkers to predict whether a drug works or causes adverse effect in patients, has emerged as an exciting new field. With the cost and hurdles for new drug approval getting increasingly higher, pharmaceutical companies have begun to explore companion tests in order to develop safer, more effective drugs. The value of CDx tests has already been demonstrated by a number of marketed products, such as HercepTest for Herceptin and K-RAS mutation tests for Erbitux and Vectibix.

Enter your details below to view the free whitepaper

By downloading this Whitepaper, you acknowledge that Global Data Plc may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Visit our Privacy Policy for more information about our services, how Global Data Plc may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.